Data:
{
"symbol": "NSRX",
"price": 3.495,
"marketCap": 30102106,
"beta": 3.963,
"lastDividend": 0,
"range": "1.98-9.99",
"change": -0.125,
"changePercentage": -3.45304,
"volume": 1895,
"averageVolume": 35806,
"companyName": "Nasus Pharma Ltd.",
"currency": "USD",
"cik": "0002029039",
"isin": "IL0012181553",
"cusip": null,
"exchangeFullName": "New York Stock Exchange Arca",
"exchange": "AMEX",
"industry": "Medical - Pharmaceuticals",
"website": "https://www.nasuspharma.com",
"description": "Nasus Pharma Ltd., a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. It offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats. The company's products include NS002, Intranasal Epinephrine for assisting in severe allergic reaction emergency situations and NS001, an Intranasal Naloxone powder nasal spray for the treatment of opioid overdose. Nasus Pharma Ltd. was incorporated in 2019 and is based in Tel Aviv-Yafo, Israel.",
"ceo": "Brendan O'Grady",
"sector": "Healthcare",
"country": "IL",
"fullTimeEmployees": "7",
"phone": "97235736632",
"address": "Yigal Alon 65",
"city": "Tel Aviv",
"state": "TA",
"zip": "6744317",
"image": "https://images.financialmodelingprep.com/symbol/NSRX.png",
"ipoDate": "2025-08-13",
"defaultImage": false,
"isEtf": false,
"isActivelyTrading": true,
"isAdr": false,
"isFund": false
}
Data:
{
"symbol": "NSRX",
"name": "Nasus Pharma Ltd.",
"price": 3.495,
"changePercentage": -3.45304,
"change": -0.125,
"volume": 1895,
"dayLow": 3.4777,
"dayHigh": 3.7,
"yearHigh": 9.99,
"yearLow": 1.98,
"marketCap": 30102106,
"priceAvg50": 3.17754,
"priceAvg200": 4.63143,
"exchange": "AMEX",
"open": 3.7,
"previousClose": 3.62,
"timestamp": 1786974626,
"chart_vwap_daily": [
{
"t": "2026-07-07",
"v": 3.2417,
"c": 3.05
},
{
"t": "2026-07-08",
"v": 3.1358,
"c": 3.1139
},
{
"t": "2026-07-09",
"v": 3.1553,
"c": 3.01
},
{
"t": "2026-07-10",
"v": 3.0702,
"c": 2.93
},
{
"t": "2026-07-13",
"v": 3.1121,
"c": 3.08
},
{
"t": "2026-07-14",
"v": 3.0238,
"c": 3.05
},
{
"t": "2026-07-15",
"v": 2.9978,
"c": 3.1173
},
{
"t": "2026-07-16",
"v": 3.068,
"c": 3.07
},
{
"t": "2026-07-17",
"v": 3.0423,
"c": 3.01
},
{
"t": "2026-07-20",
"v": 2.9875,
"c": 3.01
},
{
"t": "2026-07-21",
"v": 3.0281,
"c": 3.03
},
{
"t": "2026-07-22",
"v": 2.9378,
"c": 2.91
},
{
"t": "2026-07-23",
"v": 2.9252,
"c": 3.093
},
{
"t": "2026-07-24",
"v": 3.006,
"c": 3.12
},
{
"t": "2026-07-27",
"v": 3.0339,
"c": 3.09
},
{
"t": "2026-07-28",
"v": 3.0339,
"c": 3.03
},
{
"t": "2026-07-29",
"v": 3.1049,
"c": 3.21
},
{
"t": "2026-07-30",
"v": 3.1317,
"c": 3.18
},
{
"t": "2026-07-31",
"v": 3.1249,
"c": 3.03
},
{
"t": "2026-08-03",
"v": 3.0352,
"c": 3.19
},
{
"t": "2026-08-04",
"v": 3.3028,
"c": 3.5
},
{
"t": "2026-08-05",
"v": 3.272,
"c": 3.32
},
{
"t": "2026-08-06",
"v": 3.3451,
"c": 3.39
},
{
"t": "2026-08-07",
"v": 3.3704,
"c": 3.455
},
{
"t": "2026-08-10",
"v": 3.3844,
"c": 3.35
},
{
"t": "2026-08-11",
"v": 3.2817,
"c": 3.31
},
{
"t": "2026-08-12",
"v": 3.1901,
"c": 3.2384
},
{
"t": "2026-08-13",
"v": 3.2409,
"c": 3.2
},
{
"t": "2026-08-14",
"v": 3.4135,
"c": 3.62
},
{
"t": "2026-08-17",
"v": 3.6034,
"c": 3.4777
}
],
"vwap_summary": {
"days": 30,
"days_above": 18,
"days_below": 12,
"pct_days_above": 60,
"position": "below",
"gap_pct": -3.49,
"streak_days": 1
}
}
Data:
{
"volume": 1895,
"avgVolume": 35806,
"short_ratio": [
{
"symbol": "NSRX",
"file_date": "2026-08-14",
"date": "20260814",
"short_volume": 11881,
"short_exempt_volume": 0,
"total_volume": 19805,
"short_volume_ratio": 0.5999,
"signal": "Bearish"
}
],
"volume_profile": {
"poc": 3.0,
"vah": 3.34,
"val": 2.94,
"profile": [
{
"price": 2.88,
"volume": 800
},
{
"price": 2.89,
"volume": 0
},
{
"price": 2.9,
"volume": 4045
},
{
"price": 2.92,
"volume": 2379
},
{
"price": 2.93,
"volume": 0
},
{
"price": 2.95,
"volume": 1954
},
{
"price": 2.96,
"volume": 207
},
{
"price": 2.97,
"volume": 2629
},
{
"price": 2.99,
"volume": 10674
},
{
"price": 3.0,
"volume": 34065
},
{
"price": 3.02,
"volume": 5958
},
{
"price": 3.03,
"volume": 11320
},
{
"price": 3.04,
"volume": 6431
},
{
"price": 3.06,
"volume": 729
},
{
"price": 3.07,
"volume": 2028
},
{
"price": 3.08,
"volume": 4127
},
{
"price": 3.1,
"volume": 1753
},
{
"price": 3.11,
"volume": 1030
},
{
"price": 3.13,
"volume": 1511
},
{
"price": 3.14,
"volume": 0
},
{
"price": 3.15,
"volume": 821
},
{
"price": 3.17,
"volume": 2001
},
{
"price": 3.18,
"volume": 7527
},
{
"price": 3.2,
"volume": 8193
},
{
"price": 3.21,
"volume": 888
},
{
"price": 3.22,
"volume": 2523
},
{
"price": 3.24,
"volume": 1568
},
{
"price": 3.25,
"volume": 7766
},
{
"price": 3.26,
"volume": 26407
},
{
"price": 3.28,
"volume": 2741
},
{
"price": 3.29,
"volume": 2014
},
{
"price": 3.31,
"volume": 2107
},
{
"price": 3.32,
"volume": 356
},
{
"price": 3.33,
"volume": 14225
},
{
"price": 3.35,
"volume": 4011
},
{
"price": 3.36,
"volume": 1929
},
{
"price": 3.38,
"volume": 5247
},
{
"price": 3.39,
"volume": 4606
},
{
"price": 3.4,
"volume": 3499
},
{
"price": 3.42,
"volume": 1014
},
{
"price": 3.43,
"volume": 2586
},
{
"price": 3.44,
"volume": 2966
},
{
"price": 3.46,
"volume": 3044
},
{
"price": 3.47,
"volume": 18595
},
{
"price": 3.49,
"volume": 378
},
{
"price": 3.5,
"volume": 6938
},
{
"price": 3.51,
"volume": 2144
},
{
"price": 3.53,
"volume": 239
},
{
"price": 3.54,
"volume": 143
},
{
"price": 3.55,
"volume": 2458
},
{
"price": 3.57,
"volume": 954
},
{
"price": 3.58,
"volume": 263
},
{
"price": 3.6,
"volume": 0
},
{
"price": 3.61,
"volume": 0
},
{
"price": 3.62,
"volume": 103
},
{
"price": 3.64,
"volume": 0
},
{
"price": 3.65,
"volume": 0
},
{
"price": 3.67,
"volume": 0
},
{
"price": 3.68,
"volume": 0
},
{
"price": 3.69,
"volume": 1039
}
],
"sessions": 20
}
}
Data:
{
"symbol": "NSRX",
"marketCap": 30102106,
"enterpriseValueTTM": 30102106,
"evToSalesTTM": 0,
"evToOperatingCashFlowTTM": 0,
"evToFreeCashFlowTTM": 0,
"evToEBITDATTM": -19.765007222587,
"netDebtToEBITDATTM": 0,
"currentRatioTTM": 0,
"incomeQualityTTM": 0,
"grahamNumberTTM": null,
"grahamNetNetTTM": 0,
"taxBurdenTTM": 0.9871134020618557,
"interestBurdenTTM": 1.0190413657255417,
"workingCapitalTTM": 0,
"investedCapitalTTM": 0,
"returnOnAssetsTTM": 0,
"operatingReturnOnAssetsTTM": 0,
"returnOnTangibleAssetsTTM": 0,
"returnOnEquityTTM": 0,
"returnOnInvestedCapitalTTM": 0,
"returnOnCapitalEmployedTTM": 0,
"earningsYieldTTM": -0.0483839067239533,
"freeCashFlowYieldTTM": 0,
"capexToOperatingCashFlowTTM": 0,
"capexToDepreciationTTM": 0,
"capexToRevenueTTM": 0,
"salesGeneralAndAdministrativeToRevenueTTM": 0,
"researchAndDevelopementToRevenueTTM": 0,
"stockBasedCompensationToRevenueTTM": 0,
"intangiblesToTotalAssetsTTM": 0,
"averageReceivablesTTM": 0,
"averagePayablesTTM": 0,
"averageInventoryTTM": 0,
"daysOfSalesOutstandingTTM": 0,
"daysOfPayablesOutstandingTTM": 0,
"daysOfInventoryOutstandingTTM": 0,
"operatingCycleTTM": 0,
"cashConversionCycleTTM": 0,
"freeCashFlowToEquityTTM": 0,
"freeCashFlowToFirmTTM": 0,
"tangibleAssetValueTTM": 0,
"netCurrentAssetValueTTM": 0,
"grossProfitMarginTTM": 0,
"ebitMarginTTM": 0,
"ebitdaMarginTTM": 0,
"operatingProfitMarginTTM": 0,
"pretaxProfitMarginTTM": 0,
"continuousOperationsProfitMarginTTM": 0,
"netProfitMarginTTM": 0,
"bottomLineProfitMarginTTM": 0,
"receivablesTurnoverTTM": 0,
"payablesTurnoverTTM": 0,
"inventoryTurnoverTTM": 0,
"fixedAssetTurnoverTTM": 0,
"assetTurnoverTTM": 0,
"quickRatioTTM": 0,
"solvencyRatioTTM": 0,
"cashRatioTTM": 0,
"priceToEarningsRatioTTM": -20.558823529411764,
"priceToEarningsGrowthRatioTTM": -0.20558823529411765,
"forwardPriceToEarningsGrowthRatioTTM": -0.20558823529411765,
"priceToEarningsDilutedRatioTTM": -20.558823529411764,
"priceToEarningsDilutedGrowthRatioTTM": -0.20558823529411765,
"priceToBookRatioTTM": 0,
"priceToSalesRatioTTM": 0,
"priceToFreeCashFlowRatioTTM": 0,
"priceToOperatingCashFlowRatioTTM": 0,
"debtToAssetsRatioTTM": 0,
"debtToEquityRatioTTM": 0,
"debtToCapitalRatioTTM": 0,
"longTermDebtToCapitalRatioTTM": 0,
"financialLeverageRatioTTM": 0,
"workingCapitalTurnoverRatioTTM": 0,
"operatingCashFlowRatioTTM": 0,
"operatingCashFlowSalesRatioTTM": 0,
"freeCashFlowOperatingCashFlowRatioTTM": 0,
"debtServiceCoverageRatioTTM": 0,
"interestCoverageRatioTTM": -37.172413793103445,
"shortTermOperatingCashFlowCoverageRatioTTM": 0,
"operatingCashFlowCoverageRatioTTM": 0,
"capitalExpenditureCoverageRatioTTM": 0,
"dividendPaidAndCapexCoverageRatioTTM": 0,
"dividendPayoutRatioTTM": 0,
"dividendYieldTTM": 0,
"revenuePerShareTTM": 0,
"netIncomePerShareTTM": -0.1691017540002168,
"interestDebtPerShareTTM": 0,
"cashPerShareTTM": 0,
"bookValuePerShareTTM": 0,
"tangibleBookValuePerShareTTM": 0,
"shareholdersEquityPerShareTTM": 0,
"operatingCashFlowPerShareTTM": 0,
"capexPerShareTTM": 0,
"freeCashFlowPerShareTTM": 0,
"netIncomePerEBTTTM": 0.9871134020618557,
"ebtPerEbitTTM": 1.4397031539888683,
"priceToFairValueTTM": 0,
"debtToMarketCapTTM": 0,
"effectiveTaxRateTTM": 0,
"enterpriseValueMultipleTTM": -19.765007222587,
"dividendPerShareTTM": 0,
"revenue_history": [],
"dcf": {
"status": "not_found",
"endpoint": "dcf-advanced",
"provided": "symbol=\"NSRX\"",
"message": "No data returned for dcf-advanced with symbol=\"NSRX\". The identifier may not exist, or may have no data for this endpoint. Use the 'search' tool to verify the symbol/cik/name."
},
"statements": {
"income": [],
"balance_sheet": {
"status": "not_found",
"endpoint": "balance-sheet-statement",
"provided": "symbol=\"NSRX\"",
"message": "No data returned for balance-sheet-statement with symbol=\"NSRX\". The identifier may not exist, or may have no data for this endpoint. Use the 'search' tool to verify the symbol/cik/name."
},
"cash_flow": {
"status": "not_found",
"endpoint": "cashflow-statement",
"provided": "symbol=\"NSRX\"",
"message": "No data returned for cashflow-statement with symbol=\"NSRX\". The identifier may not exist, or may have no data for this endpoint. Use the 'search' tool to verify the symbol/cik/name."
}
}
}
Data:
{
"price": 3.495,
"rsi": 57.55631368851951,
"sma20": 3.23825,
"sma50": 3.1828999999999996,
"sma200": 4.607024999999998,
"adx": 26.159248197590305,
"atr": 0.32,
"atr_pct": 9.16,
"high_52w": 9.15,
"low_52w": 2.01,
"structure": {
"ema8": 3.384426596547179,
"ema21": 3.2843046017929622,
"ema50": 3.223286210944161,
"ema200": 4.3890161916165695,
"checks": {
"price_above_all": false,
"ema_stacked": true,
"ema21_rising": true,
"ema50_rising": true,
"adx_over_30": false,
"higher_highs_lows": true,
"near_21ema": true
},
"dist_21ema_pct": 6.4,
"macd": {
"macd": 0.081,
"signal": 0.055,
"histogram": 0.026
},
"bollinger": {
"mid": 3.24,
"upper": 3.61,
"lower": 2.87,
"width_pct": 22.78
},
"crossover": {
"fresh_cross": false,
"pre_compressed": true,
"held_above_21": false,
"candles_since": 10,
"intraday_support": false
},
"momentum": {
"roc10": 9.6,
"checks": {
"roc_over_5": true,
"rsi_in_band": true,
"macd_expanding": true,
"top_quartile_3d": false,
"no_big_down": true,
"near_high": false
},
"volume": {
"rvol": 0.13,
"checks": {
"rvol_over_2": false,
"up_vol_beats_down": true,
"obv_new_high": false,
"surge_day": true,
"pullback_declining_vol": false,
"last_up_beats_down": true
}
}
},
"relative_strength": {
"sector": "Healthcare",
"sector_etf": "XLV",
"sector_etf_ret10d": 2.97,
"checks": {
"beats_spy_all": true,
"beats_sector_10d": true,
"rs_line_at_high": false,
"sector_top3": false
}
},
"commodity": {},
"universe": {
"checks": {
"price_over_20": false,
"avg_vol_over_2m": false,
"mcap_over_1b": false,
"no_earnings_7d": null,
"not_lev_etf_spac": true,
"bidask_spread": null,
"dollar_vol_over_10m": false
},
"avg_dollar_vol": 125141.97,
"avg_vol": 35806
},
"options": {}
}
}
Data:
{
"prior_day": {
"high": 3.7,
"low": 3.48,
"close": 3.48,
"date": "2026-08-17"
},
"woodie_pivots": {
"PP": 3.53,
"R1": 3.59,
"S1": 3.37,
"R2": 3.76,
"S2": 3.31
},
"swing": {
"high_20d": 3.7,
"low_20d": 2.87,
"high_60d": 3.7,
"low_60d": 2.71
},
"orb": {
"high": 3.7,
"low": 3.48,
"date": "2026-08-17"
},
"vwap": 3.61,
"volume_profile": {
"poc": 3.0,
"vah": 3.34,
"val": 2.94,
"sessions": 20
},
"recent_daily": [
{
"d": "2026-07-14",
"o": 3.195,
"h": 3.195,
"l": 2.95,
"c": 3.05,
"v": 13278.718879
},
{
"d": "2026-07-15",
"o": 2.938,
"h": 3.1173,
"l": 2.938,
"c": 3.1173,
"v": 6266.3545
},
{
"d": "2026-07-16",
"o": 3.01,
"h": 3.19,
"l": 3,
"c": 3.07,
"v": 7310.2171
},
{
"d": "2026-07-17",
"o": 2.93,
"h": 3.096,
"l": 2.93,
"c": 3.01,
"v": 6770.3545
},
{
"d": "2026-07-20",
"o": 2.96,
"h": 3.02,
"l": 2.96,
"c": 3.01,
"v": 4580.3545
},
{
"d": "2026-07-21",
"o": 3.03,
"h": 3.03,
"l": 3.02,
"c": 3.03,
"v": 5459.715
},
{
"d": "2026-07-22",
"o": 2.9,
"h": 3.06,
"l": 2.9,
"c": 2.91,
"v": 6088.776907
},
{
"d": "2026-07-23",
"o": 2.9,
"h": 3.093,
"l": 2.8704,
"c": 3.093,
"v": 9650.624596
},
{
"d": "2026-07-24",
"o": 2.92,
"h": 3.15,
"l": 2.92,
"c": 3.12,
"v": 37209.6522
},
{
"d": "2026-07-27",
"o": 3.08,
"h": 3.1,
"l": 2.9601,
"c": 3.09,
"v": 12343.3545
},
{
"d": "2026-07-28",
"o": 2.96,
"h": 3.15,
"l": 2.96,
"c": 3.03,
"v": 16555.3545
},
{
"d": "2026-07-29",
"o": 2.98,
"h": 3.25,
"l": 2.97,
"c": 3.21,
"v": 12565.47467
},
{
"d": "2026-07-30",
"o": 3.02,
"h": 3.19,
"l": 3.02,
"c": 3.18,
"v": 2437.212492
},
{
"d": "2026-07-31",
"o": 2.96,
"h": 3.22,
"l": 2.96,
"c": 3.03,
"v": 5738.3785
},
{
"d": "2026-08-03",
"o": 3.04,
"h": 3.19,
"l": 2.97,
"c": 3.19,
"v": 8246.441199
},
{
"d": "2026-08-04",
"o": 3.2,
"h": 3.6,
"l": 3.15,
"c": 3.5,
"v": 70566.889455
},
{
"d": "2026-08-05",
"o": 3.47,
"h": 3.57,
"l": 3.15,
"c": 3.32,
"v": 19890.6714
},
{
"d": "2026-08-06",
"o": 3.22,
"h": 3.4999,
"l": 3.1,
"c": 3.39,
"v": 11659.255371
},
{
"d": "2026-08-07",
"o": 3.18,
"h": 3.57,
"l": 3.14,
"c": 3.455,
"v": 9366.6714
},
{
"d": "2026-08-10",
"o": 3.26,
"h": 3.51,
"l": 3.21,
"c": 3.35,
"v": 15386.699004
},
{
"d": "2026-08-11",
"o": 3.4,
"h": 3.4,
"l": 3.2241,
"c": 3.31,
"v": 4108.323372
},
{
"d": "2026-08-12",
"o": 3.186,
"h": 3.2384,
"l": 3.13,
"c": 3.2384,
"v": 3142.666293
},
{
"d": "2026-08-13",
"o": 3.08,
"h": 3.49,
"l": 3.05,
"c": 3.2,
"v": 6838.6714
},
{
"d": "2026-08-14",
"o": 3.2,
"h": 3.64,
"l": 3.2,
"c": 3.62,
"v": 27500.693682
},
{
"d": "2026-08-17",
"o": 3.7,
"h": 3.7,
"l": 3.4777,
"c": 3.4777,
"v": 1795.938517
}
]
}
Data:
{
"estimates": {
"status": "not_found",
"endpoint": "financial-estimates",
"provided": "symbol=\"NSRX\"",
"message": "No data returned for financial-estimates with symbol=\"NSRX\". The identifier may not exist, or may have no data for this endpoint. Use the 'search' tool to verify the symbol/cik/name."
},
"price_target": {
"symbol": "NSRX",
"targetHigh": 22,
"targetLow": 22,
"targetConsensus": 22,
"targetMedian": 22
},
"ratings": {
"status": "not_found",
"endpoint": "ratings-snapshot",
"provided": "symbol=\"NSRX\"",
"message": "No data returned for ratings-snapshot with symbol=\"NSRX\". The identifier may not exist, or may have no data for this endpoint. Use the 'search' tool to verify the symbol/cik/name."
},
"grades": [
{
"symbol": "NSRX",
"date": "2026-03-26",
"gradingCompany": "Citizens",
"previousGrade": "Market Outperform",
"newGrade": "Market Outperform",
"action": "maintain"
}
]
}
Data:
[
{
"title": "Nasus Pharma H1 EPS $(0.54) Misses $(0.20) Estimate",
"url": "https://www.benzinga.com/news/earnings/26/08/61243652/nasus-pharma-h1-eps-0-54-misses-0-20-estimate",
"source": "benzinga",
"date": "2026-08-17T12:15:47.042000+00:00",
"summary": "Nasus Pharma (AMEX:NSRX) reported quarterly losses of $(0.54) per share which missed the analyst consensus estimate of $(0.20) by 170 percent. This is a 217.65 percent decrease over losses of $(0.17) per share from the",
"image": ""
},
{
"title": "Nasus Pharma Reports First Half 2026 Financial Results and Provides Business Update",
"url": "https://www.globenewswire.com/news-release/2026/08/17/3346073/0/en/nasus-pharma-reports-first-half-2026-financial-results-and-provides-business-update.html",
"source": "GlobeNewsWire",
"date": "2026-08-17 08:14:00",
"summary": "Appointed Pharma Industry Veteran\u00a0 Brendan O'Grady as Chief Executive Officer Company on Track to Advance Clinical Programs to Key Second Half 2026 Milestones TEL AVIV, Israel, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) (\"Nasus\", \u201cNasus Pharma\u201d or the \"Compa",
"image": "https://images.financialmodelingprep.com/news/nasus-pharma-reports-first-half-2026-financial-results-and-20260817.jpg"
},
{
"title": "Nasus Pharma (NYSEAMERICAN:NSRX) Trading Up 9.7% \u2013 Here\u2019s Why",
"url": "https://www.defenseworld.net/2026/08/05/nasus-pharma-nyseamericannsrx-trading-up-9-7-heres-why.html",
"source": "Defense World",
"date": "2026-08-05 03:01:40",
"summary": "Nasus Pharma Ltd. (NYSEAMERICAN:NSRX - Get Free Report)'s share price was up 9.7% during mid-day trading on Tuesday. The stock traded as high as $3.60 and last traded at $3.50. Approximately 70,095 shares changed hands during mid-day trading, an increase of 487% from the average ",
"image": "https://images.financialmodelingprep.com/news/nasus-pharma-nyseamericannsrx-trading-up-97-heres-why-20260805.png"
},
{
"title": "Nasus Pharma Appoints Pharmaceutical Industry Veteran Brendan P. O'Grady as Chief Executive Officer to Lead Strategic Growth",
"url": "https://www.globenewswire.com/news-release/2026/07/28/3334132/0/en/Nasus-Pharma-Appoints-Pharmaceutical-Industry-Veteran-Brendan-P-O-Grady-as-Chief-Executive-Officer-to-Lead-Strategic-Growth.html",
"source": "GlobeNewswire Inc.",
"date": "2026-07-28T11:30:00Z",
"summary": "Nasus Pharma Ltd. (NYSE: NSRX) announced the appointment of Brendan P. O'Grady as Chief Executive Officer, effective July 27, 2026. O'Grady, a pharmaceutical industry veteran with 35 years of experience and former CEO of Teva USA, will lead the company's growth strategy with focu",
"image": "https://ml.globenewswire.com/Resource/Download/3e1c3580-2a9c-4630-9a15-8fb1333bac9d"
},
{
"title": "Life Sciences Virtual Investor Forum Presentations Now Available for On-Demand Viewing",
"url": "https://www.globenewswire.com/news-release/2026/06/26/3318215/0/en/Life-Sciences-Virtual-Investor-Forum-Presentations-Now-Available-for-On-Demand-Viewing.html",
"source": "GlobeNewswire Inc.",
"date": "2026-06-26T12:35:00Z",
"summary": "Virtual Investor Conferences announced that presentations from the June 24-25 Life Sciences Virtual Investor Forum are now available for on-demand viewing for 90 days. Twenty companies across the life sciences sector presented at the forum, with select companies still accepting 1",
"image": "https://ml.globenewswire.com/Resource/Download/861fb541-7064-4cf4-a563-37472ff71760"
},
{
"title": "Nasus Pharma to Participate in the Zacks Life Sciences Investor Forum",
"url": "https://www.globenewswire.com/news-release/2026/06/22/3315245/0/en/nasus-pharma-to-participate-in-the-zacks-life-sciences-investor-forum.html",
"source": "GlobeNewsWire",
"date": "2026-06-22 08:00:00",
"summary": "TEL AVIV, Israel, June 22, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) (\u201cNasus Pharma\u201d or the \u201cCompany\u201d), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced that the Company's management will present l",
"image": "https://images.financialmodelingprep.com/news/nasus-pharma-to-participate-in-the-zacks-life-sciences-20260622.jpg"
},
{
"title": "Nasus Pharma Announces Positive Results from Preclinical Pharmacokinetic and Safety Study of Intranasal Ondansetron (NS003)",
"url": "https://www.globenewswire.com/news-release/2026/06/09/3308784/0/en/nasus-pharma-announces-positive-results-from-preclinical-pharmacokinetic-and-safety-study-of-intranasal-ondansetron-ns003.html",
"source": "GlobeNewsWire",
"date": "2026-06-09 08:00:00",
"summary": "Study Comparing Intranasal Powder Formulation of Ondansetron Demonstrates Comparable Pharmacokinetic Profile to Intravenous Ondansetron in Animal Study;\u00a0 Program to Advance to First-in-Human PK Study in Third Quarter of 2026 TEL AVIV, Israel, June 09, 2026 (GLOBE NEWSWIRE) -- Nas",
"image": "https://images.financialmodelingprep.com/news/nasus-pharma-announces-positive-results-from-preclinical-pharmacokinetic-and-20260609.jpg"
},
{
"title": "Nasus Pharma to Host Virtual KOL Event on June 10, 2026 to Discuss NS002 for the Treatment of Anaphylaxis",
"url": "https://www.globenewswire.com/news-release/2026/06/01/3304316/0/en/nasus-pharma-to-host-virtual-kol-event-on-june-10-2026-to-discuss-ns002-for-the-treatment-of-anaphylaxis.html",
"source": "GlobeNewsWire",
"date": "2026-06-01 08:00:00",
"summary": "TEL AVIV, Israel, June 01, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) (\u201cNasus Pharma\u201d or the \u201cCompany\u201d), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced that it will host a virtual key opinion lead",
"image": "https://images.financialmodelingprep.com/news/nasus-pharma-to-host-virtual-kol-event-on-june-20260601.jpg"
},
{
"title": "Nasus Pharma Advances NS002 Towards Pivotal Study Following Positive Phase 2; Reports Annual Results and Provides Business Update",
"url": "https://www.globenewswire.com/news-release/2026/03/25/3262206/0/en/Nasus-Pharma-Advances-NS002-Towards-Pivotal-Study-Following-Positive-Phase-2-Reports-Annual-Results-and-Provides-Business-Update.html",
"source": "GlobeNewswire Inc.",
"date": "2026-03-25T13:00:00Z",
"summary": "Nasus Pharma reported positive Phase 2 results for NS002, its intranasal epinephrine powder, demonstrating statistically significant improvements in absorption speed compared to EpiPen\u00ae. The company plans to initiate a pivotal study in Q4 2026 and is advancing pipeline candidates",
"image": "https://ml-eu.globenewswire.com/Resource/Download/635331e1-7b05-412a-b2db-eebfda31ae81"
},
{
"title": "Nasus Pharma to Participate in Upcoming Investor Conferences",
"url": "https://www.globenewswire.com/news-release/2026/02/20/3241886/0/en/Nasus-Pharma-to-Participate-in-Upcoming-Investor-Conferences.html",
"source": "GlobeNewswire Inc.",
"date": "2026-02-20T13:00:00Z",
"summary": "Nasus Pharma Ltd. (NYSE: NSRX), a clinical-stage pharmaceutical company developing intranasal products, announced that CEO Dan Teleman will present at three upcoming investor conferences: Oppenheimer 36th Annual Healthcare Life Sciences Conference (Feb 25), BIO Investment & Growt",
"image": "https://ml-eu.globenewswire.com/Resource/Download/635331e1-7b05-412a-b2db-eebfda31ae81"
},
{
"title": "Nasus Pharma Announces Closing of $15.0 Million Private Placement",
"url": "https://www.globenewswire.com/news-release/2026/02/13/3238057/0/en/Nasus-Pharma-Announces-Closing-of-15-0-Million-Private-Placement.html",
"source": "GlobeNewswire Inc.",
"date": "2026-02-13T13:00:00Z",
"summary": "Nasus Pharma Ltd. (NYSE: NSRX) announced the closing of a private placement raising approximately $15.0 million gross proceeds through the sale of 2,695,425 ordinary shares and accompanying warrants at $5.565 per share. The company plans to use the proceeds to advance its NS002 i",
"image": "https://ml-eu.globenewswire.com/Resource/Download/635331e1-7b05-412a-b2db-eebfda31ae81"
},
{
"title": "Nasus Pharma Announces Pricing of $15.0 Million Private Placement",
"url": "https://www.globenewswire.com/news-release/2026/02/11/3235899/0/en/Nasus-Pharma-Announces-Pricing-of-15-0-Million-Private-Placement.html",
"source": "GlobeNewswire Inc.",
"date": "2026-02-11T04:03:00Z",
"summary": "Nasus Pharma Ltd. (NYSE: NSRX), a clinical-stage pharmaceutical company, announced a private placement of 2.7 million ordinary shares and warrants for approximately $15 million in gross proceeds. The funds will be used to advance pivotal clinical development of NS002, an intranas",
"image": "https://ml.globenewswire.com/Resource/Download/3e1c3580-2a9c-4630-9a15-8fb1333bac9d"
},
{
"title": "Nasus Pharma Announces Positive Interim Results from Phase 2 Clinical Study of NS002 Intranasal Epinephrine Powder",
"url": "https://www.globenewswire.com/news-release/2026/01/20/3221623/0/en/Nasus-Pharma-Announces-Positive-Interim-Results-from-Phase-2-Clinical-Study-of-NS002-Intranasal-Epinephrine-Powder.html",
"source": "GlobeNewswire Inc.",
"date": "2026-01-20T13:00:00Z",
"summary": "Nasus Pharma reported positive interim Phase 2 results for NS002, its intranasal epinephrine powder for anaphylaxis treatment. The drug demonstrated faster absorption and higher peak epinephrine levels compared to EpiPen, with 91% of participants reaching therapeutic levels at 5 ",
"image": "https://ml-eu.globenewswire.com/Resource/Download/635331e1-7b05-412a-b2db-eebfda31ae81"
}
]
Data:
[
{
"symbol": "NSRX",
"date": "2026-07-01",
"epsActual": null,
"epsEstimated": -0.27,
"revenueActual": null,
"revenueEstimated": null,
"lastUpdated": "2026-08-17"
}
]
Data:
{
"borrow": [],
"short_interest": [
{
"symbol": "NSRX",
"file_date": "",
"error": "Symbol not found in FINRA biweekly file",
"days_to_cover": null
}
],
"ftd": {
"symbol": "NSRX",
"periods": [
{
"file_period": "202604a",
"settlement_date": "20260410",
"quantity_fails": 339,
"price": 2.32
},
{
"file_period": "202604b",
"settlement_date": "20260429",
"quantity_fails": 237,
"price": 2.91
},
{
"file_period": "202606a",
"settlement_date": "20260612",
"quantity_fails": 1697,
"price": 3.17
},
{
"file_period": "202606b",
"settlement_date": "20260630",
"quantity_fails": 1129,
"price": 3.45
},
{
"file_period": "202607a",
"settlement_date": "20260714",
"quantity_fails": 688,
"price": 3.08
},
{
"file_period": "202607b",
"settlement_date": "20260724",
"quantity_fails": 542,
"price": 3.09
}
],
"trend": "rising",
"trend_description": "FTD quantity increasing \u2014 settlement pressure building, potential squeeze precursor"
}
}
Data:
{
"insider": [
{
"symbol": "NSRX",
"filingDate": "2026-07-31",
"transactionDate": "2026-07-27",
"reportingCik": "0001726533",
"companyCik": "0002029039",
"transactionType": "",
"securitiesOwned": 0,
"reportingName": "O'Grady Brendan P.",
"typeOfOwner": "director, officer: Chief Executive Officer",
"acquisitionOrDisposition": "",
"directOrIndirect": null,
"formType": "3",
"securitiesTransacted": 0,
"price": 0,
"securityName": "",
"url": "https://www.sec.gov/Archives/edgar/data/2029039/000149315226035646/0001493152-26-035646-index.htm"
},
{
"symbol": "NSRX",
"filingDate": "2026-07-29",
"transactionDate": "2026-07-22",
"reportingCik": "0002122500",
"companyCik": "0002029039",
"transactionType": "",
"securitiesOwned": 0,
"reportingName": "Teleman Dan Benjamin",
"typeOfOwner": "director, officer: Chief Executive Officer",
"acquisitionOrDisposition": "",
"directOrIndirect": null,
"formType": "4",
"securitiesTransacted": 0,
"price": 0,
"securityName": "",
"url": "https://www.sec.gov/Archives/edgar/data/2029039/000149315226035218/0001493152-26-035218-index.htm"
},
{
"symbol": "NSRX",
"filingDate": "2026-06-22",
"transactionDate": "2026-06-17",
"reportingCik": "0002122500",
"companyCik": "0002029039",
"transactionType": "P-Purchase",
"securitiesOwned": 163541,
"reportingName": "Teleman Dan Benjamin",
"typeOfOwner": "director, officer: Chief Executive Officer",
"acquisitionOrDisposition": "A",
"directOrIndirect": "D",
"formType": "4",
"securitiesTransacted": 6550,
"price": 3.1,
"securityName": "Ordinary Shares",
"url": "https://www.sec.gov/Archives/edgar/data/2029039/000149315226029484/0001493152-26-029484-index.htm"
},
{
"symbol": "NSRX",
"filingDate": "2026-04-22",
"transactionDate": "2026-04-22",
"reportingCik": "0002122500",
"companyCik": "0002029039",
"transactionType": "P-Purchase",
"securitiesOwned": 156991,
"reportingName": "Teleman Dan Benjamin",
"typeOfOwner": "director, officer: Chief Executive Officer",
"acquisitionOrDisposition": "A",
"directOrIndirect": "D",
"formType": "4",
"securitiesTransacted": 2900,
"price": 3.76,
"securityName": "Ordinary Shares",
"url": "https://www.sec.gov/Archives/edgar/data/2029039/000149315226018607/0001493152-26-018607-index.htm"
},
{
"symbol": "NSRX",
"filingDate": "2026-04-01",
"transactionDate": "2026-03-31",
"reportingCik": "0002122500",
"companyCik": "0002029039",
"transactionType": "P-Purchase",
"securitiesOwned": 21246,
"reportingName": "Teleman Dan Benjamin",
"typeOfOwner": "director, officer: Chief Executive Officer",
"acquisitionOrDisposition": "A",
"directOrIndirect": "D",
"formType": "4",
"securitiesTransacted": 15000,
"price": 2.04,
"securityName": "Ordinary Shares",
"url": "https://www.sec.gov/Archives/edgar/data/2029039/000149315226014503/0001493152-26-014503-index.htm"
},
{
"symbol": "NSRX",
"filingDate": "2026-03-27",
"transactionDate": "2026-11-20",
"reportingCik": "0001721411",
"companyCik": "0002029039",
"transactionType": "",
"securitiesOwned": 0,
"reportingName": "Rubin Eyal",
"typeOfOwner": "officer, other: Chief Financial Officer",
"acquisitionOrDisposition": "",
"directOrIndirect": "D",
"formType": "3",
"securitiesTransacted": 40549,
"price": 7.56,
"securityName": "Share options (right to buy)",
"url": "https://www.sec.gov/Archives/edgar/data/2029039/000149315226013399/0001493152-26-013399-index.htm"
},
{
"symbol": "NSRX",
"filingDate": "2026-03-27",
"transactionDate": "2026-03-11",
"reportingCik": "0001867998",
"companyCik": "0002029039",
"transactionType": "",
"securitiesOwned": 0,
"reportingName": "Silberman David",
"typeOfOwner": "director",
"acquisitionOrDisposition": "",
"directOrIndirect": "D",
"formType": "3",
"securitiesTransacted": 10000,
"price": 5.38,
"securityName": "Share Option (right to buy)",
"url": "https://www.sec.gov/Archives/edgar/data/2029039/000149315226013388/0001493152-26-013388-index.htm"
},
{
"symbol": "NSRX",
"filingDate": "2026-03-27",
"transactionDate": "2026-03-18",
"reportingCik": "0002122500",
"companyCik": "0002029039",
"transactionType": "",
"securitiesOwned": 6246,
"reportingName": "Teleman Dan Benjamin",
"typeOfOwner": "director, officer: Chief Executive Officer",
"acquisitionOrDisposition": "",
"directOrIndirect": "D",
"formType": "3",
"securitiesTransacted": 0,
"price": 0,
"securityName": "Ordinary Shares",
"url": "https://www.sec.gov/Archives/edgar/data/2029039/000149315226013389/0001493152-26-013389-index.htm"
}
],
"congress": [
"status",
"endpoint",
"provided",
"message",
"status",
"endpoint",
"provided",
"message"
],
"dark_pool": [
{
"ticker": "NSRX",
"executed_at": "2026-08-17T13:42:17.889000Z",
"size": 700.0,
"price": 3.4777,
"premium": 2434.39,
"volume": 700.0,
"trade_code": " "
}
],
"ats": {
"symbol": "NSRX",
"date": "20260814",
"ats_volume": 0,
"total_volume": 19805,
"ats_ratio": 0.0,
"ats_pct": 0.0,
"signal": "Low",
"history": [
{
"date": "20260814",
"ats_ratio": 0.0
},
{
"date": "20260813",
"ats_ratio": 0.0
},
{
"date": "20260812",
"ats_ratio": 0.0
},
{
"date": "20260811",
"ats_ratio": 0.0
},
{
"date": "20260810",
"ats_ratio": 0.0
}
]
},
"polygon_dp": {
"ticker": "NSRX",
"days": [
{
"date": "2026-08-17",
"close": 3.4777,
"vwap": 3.6,
"volume": 1795,
"vwap_discount_pct": 3.61
},
{
"date": "2026-08-14",
"close": 3.62,
"vwap": 3.41,
"volume": 27500,
"vwap_discount_pct": -5.7
},
{
"date": "2026-08-13",
"close": 3.2,
"vwap": 3.24,
"volume": 6838,
"vwap_discount_pct": 1.28
},
{
"date": "2026-08-12",
"close": 3.2384,
"vwap": 3.19,
"volume": 3142,
"vwap_discount_pct": -1.49
},
{
"date": "2026-08-11",
"close": 3.31,
"vwap": 3.28,
"volume": 4108,
"vwap_discount_pct": -0.85
}
],
"avg_vwap_discount_pct": -0.63,
"signal": "Distribution"
},
"options_flow": [],
"net_premium": {
"ticker": "NSRX",
"net_call_premium": null,
"net_put_premium": null,
"call_premium": null,
"put_premium": null,
"bullish_premium": null,
"bearish_premium": null,
"put_call_ratio": null,
"iv_rank": null,
"implied_move_perc": null,
"gex_ratio": null,
"gex_net_change": null
},
"hot_chains": [],
"gamma_profile": {
"ticker": "NSRX"
},
"oi_changes": {}
}
Data:
{
"vix": 14.55,
"sp500": 7748.5,
"fed_funds": 3.63,
"yield_curve_10y2y": 0.48,
"hy_spread": 2.72,
"treasury": {
"date": "2026-08-14",
"month1": 3.79,
"month2": 3.81,
"month3": 3.86,
"month6": 3.95,
"year1": 3.98,
"year2": 4.17,
"year3": 4.24,
"year5": 4.36,
"year7": 4.51,
"year10": 4.68,
"year20": 5.25,
"year30": 5.25
},
"events": [
{
"title": "FOMC Meeting Minutes",
"currency": "USD",
"date": "2026-08-19",
"time_utc": "18:00",
"impact": "High",
"forecast": null,
"previous": null,
"actual": null,
"minutes_until": 3166
}
]
}
Data:
{
"days": 93,
"patterns": [
{
"name": "VWAP Touch",
"count": 93,
"pct": 100
},
{
"name": "9 EMA Touch",
"count": 93,
"pct": 100
},
{
"name": "21 EMA Touch",
"count": 93,
"pct": 100
},
{
"name": "ORB Breakout",
"count": 87,
"pct": 94
},
{
"name": "Woodie Pivot Touch",
"count": 86,
"pct": 92
},
{
"name": "Darvas Box",
"count": 83,
"pct": 89
},
{
"name": "PDH/PDL Touch",
"count": 74,
"pct": 80
},
{
"name": "Gap Fill",
"count": 69,
"pct": 74
},
{
"name": "Power Hour",
"count": 38,
"pct": 41
},
{
"name": "High Vol Open",
"count": 35,
"pct": 38
},
{
"name": "Open Retracement",
"count": 30,
"pct": 32
}
]
}